Day: February 8, 2025

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions. The data were presented today at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) 2025 annual meeting and will support the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA)...

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg maintained visual and anatomic improvements while rapidly extending their dosing intervals: 79%, 43% and 16% achieved last assigned dosing intervals of ≥3, ≥4 and ≥5 months, respectively Results add to growing body of evidence showing ability of EYLEA HD to extend dosing intervals, including previously presented data in diabetic macular edema following three years of EYLEA HD treatment in which 88%, 68%,...

3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks In the recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and 4FRONT-2 patient populations, 87% required 0-1 supplemental injection and 80% were injection-free through 52 weeks Durable and stable aflibercept expression demonstrated across all 3E10 vg/eye PRISM cohorts, with up to two years of follow-up 4D-150 continues to be well tolerated, with up to three years of follow-up 4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively Company to host webcast on Monday, February 10, 2025 at 8:00 a.m. ETEMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT...

SINGAPORE, Feb. 08, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG), an innovative provider of integrated solutions consisting of efficient mining products for altcoins, is excited to announce its launch of the AE BOX under its Goldshell brand on 7 February 2025. The AE BOX, ICG’s first ALEO miner, has a hashrate mode of 37 MH/s±5%, a default hashrate power of 360W±5% and a default hashrate power consumption of 9.73J/MH. The AE BOX promises to empower users to build their own projects in a privacy-focused, decentralised blockchain platform. Mr Charles Yan, Chief Financial Officer of ICG, said: “The AE BOX enables us to introduce the promising world of ALEO’s zero-knowledge proofing technology to our users. The world of crypto rapidly evolves, and the launch of the AE BOX aims to place our users at the forefront of...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 07, 2025 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (“Mustang” or the “Company”) is pleased to announce a non-brokered private placement consisting of up to 6,000,000 units of the Company (each, a “Unit”), at a price of $0.20 per Unit, for gross proceeds of up to $1,200,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one (1) Common Share purchase warrant (each, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”, and collectively with the Common Shares and Warrants, the “Securities”) at a price of $0.27 per Warrant Share for a period of eight...

PITTSBURGH, Feb. 07, 2025 (GLOBE NEWSWIRE) — Matthews International Corporation (Nasdaq GSM: MATW) (“Matthews” or the “Company”) issued the following statement regarding a February 6, 2025 report by Institutional Shareholder Services (“ISS”): We strongly disagree with ISS’ recommendation, which adopts Barington’s positions while giving no substantive analysis to Barington’s own plans and nominees. In doing so, ISS does not give appropriate consideration to the concerning absence of relevant skills and new ideas among Barington’s nominees and the actions Matthews is taking to unlock the value of its businesses. Notably, Barington’s “four-step plan” contains no ideas that would help shareholders, except those (like a strategic transaction of SGK) that have already been initiated by the Company. ISS’ report does not address...